organophosphonates has been researched along with rosiglitazone in 2 studies
| Studies (organophosphonates) | Trials (organophosphonates) | Recent Studies (post-2010) (organophosphonates) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 9,968 | 880 | 3,596 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | organophosphonates (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Authier, H; Auwerx, J; Balard, P; Benoit-Vical, F; Berry, A; Chambon, P; Coste, A; Desvergne, B; Lagane, C; Lepert, JC; Magnaval, JF; Metzger, D; Olagnier, D; Pipy, B; Séguéla, JP; Wahli, W | 1 |
| Andrade, L; Libório, AB; Pereira, LV; Sanches, TR; Seguro, AC; Shimizu, MH | 1 |
2 other study(ies) available for organophosphonates and rosiglitazone
| Article | Year |
|---|---|
IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.
Topics: Anilides; Animals; Arachidonic Acids; CD36 Antigens; Cell Line, Tumor; DNA; Enzyme Inhibitors; Erythrocytes; Gene Expression; Humans; Hypoglycemic Agents; Interleukin-13; Macrophages; Macrophages, Peritoneal; Mice; Monocytes; Organophosphonates; Phagocytosis; Phospholipases A; Phospholipases A2; Plasmodium falciparum; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Transfection | 2007 |
Rosiglitazone reverses tenofovir-induced nephrotoxicity.
Topics: Adenine; Animals; Drug-Related Side Effects and Adverse Reactions; Glomerular Filtration Rate; Hypoglycemic Agents; Hypophosphatemia; Hypophosphatemia, Familial; Kidney Diseases; Male; Membrane Transport Proteins; Organophosphonates; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rosiglitazone; Tenofovir; Thiazolidinediones | 2008 |